GleamWall
中文EN

PTPI Petros Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—

Margins

Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%

Returns

ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue——————$725,403$1.58M
Cost of revenue——————$264,754$287,005
Gross profit——————$460,649$1.29M
R&D expense——————$101,945$588,355
SG&A expense$988,501$1.03M$391,486$990,737$1.80M$1.46M$577,554$1.20M
Operating income-$988,501-$1.03M-$391,486-$990,737-$1.80M-$1.46M-$577,554-$1.20M
Pretax income-$955,625-$987,036-$336,506-$922,723-$2.04M-$1.20M-$552,813-$919,541
Net income-$955,625-$987,036-$336,506-$922,723$5.43M-$2.26M-$9.27M-$2.22M
EBITDA——————$78,539-$457,910
EPS (basic)-0.30-0.03—-0.03-1.20-9.37—-16.65
EPS (diluted)-0.30-0.03—-0.03-1.20-9.37—-16.65
Weighted avg. shares (diluted)47.39M46.22M—42.28M25.92M1.16M—393,192
Banking
Net interest income$31,976$40,143$53,280$67,014$88,849$47,790$24,741$75,818
Balance sheet
Cash & equivalents$3.49M$4.35M$5.14M$6.07M$7.32M$8.93M$1.72M$3.20M
Receivables——————$416,076$1.95M
Inventory——————$1.35M$1.41M
Current assets$3.55M$4.39M$5.16M$6.13M$7.40M$14.47M$7.29M$10.72M
PP&E, net——————$22,948$18,819
Intangibles——————$3.20M$6.83M
Total assets$3.55M$4.39M$5.16M$6.13M$7.40M$17.61M$10.64M$20.69M
Current liabilities$2.84M$2.62M$2.29M$2.77M$2.95M$27.13M$18.03M$12.56M
Total liabilities$2.84M$2.62M$2.29M$2.77M$2.95M$27.19M$18.10M$17.58M
Shareholders' equity$700,894$1.77M$2.87M$3.37M$4.45M-$9.58M-$7.47M$3.12M
Shares outstanding42.37M42.37M42.28M42.28M42.28M2.05M421,12410.01M
Cash flow statement
Operating cash flow-$863,855-$784,272-$933,544-$1.13M-$3.01M-$1.66M$965,405-$771,246
Capital expenditure——————$5,449—
Free cash flow——————$959,956—
Investing cash flow——————-$5,449—
Financing cash flow——$0-$117,311-$428,233$8.71M-$1.14M-$2.77M
Depreciation & amortization——————$656,093$739,449
Stock-based compensation$117,906$120,319——$74,321$80,038$0$0

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.